glp-1 marketing The Moment: What Healthcare Marketers Can Learn from the Fastest-Growing Category in Pharma GLP-1 Drugs and Consumer Preferences:

Yes, there were human studies with BPC-157 showing no known adverse effects and safety, however since those two initial trials it appears almost all the data has been in animal models, with a few, small studies here and there for human use

We hypothesize that this limited effect may also be attributable to a narrow dosing window within which a p53-specific effect may be observed

The result builds gradually, over months, as the body remodels its own structural support

Prenatal and early life exposure to air pollution induced hippocampal vascular leakage and impaired neurogenesis in association with behavioral deficits

There will be winners and losers